skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials

Human psychopharmacology, 2005-07, Vol.20 (5), p.327-341 [Peer Reviewed Journal]

Copyright © 2005 John Wiley & Sons, Ltd. ;Copyright (c) 2005 John Wiley & Sons, Ltd. ;ISSN: 0885-6222 ;EISSN: 1099-1077 ;DOI: 10.1002/hup.696 ;PMID: 15912562

Full text available

Citations Cited by
  • Title:
    Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials
  • Author: Hudson, James I. ; Wohlreich, Madelaine M. ; Kajdasz, Daniel K. ; Mallinckrodt, Craig H. ; Watkin, John G. ; Martynov, Oleg V.
  • Subjects: Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antidepressive Agents - adverse effects ; Body Weight - drug effects ; Depressive Disorder, Major - drug therapy ; duloxetine ; Duloxetine Hydrochloride ; Female ; Humans ; major depressive disorder ; Male ; Middle Aged ; Placebos ; Randomized Controlled Trials as Topic ; safety ; Sexual Behavior - drug effects ; Thiophenes - adverse effects ; tolerability
  • Is Part Of: Human psychopharmacology, 2005-07, Vol.20 (5), p.327-341
  • Description: Objective To examine the safety and tolerability of the antidepressant duloxetine across multiple studies for major depressive disorder (MDD). Method Safety data were integrated from the acute phases of eight double‐blind, placebo‐controlled trials in which patients were randomized to duloxetine (40–120 mg/d; n = 1139) or placebo (n = 777) for up to 9 weeks. This data set included all acute‐phase clinical trials that formed the basis of the New Drug Application (United States) or European Union submission package for duloxetine in the treatment of MDD. Two studies included continuation phases in which acute treatment responders received duloxetine or placebo for an additional 26 weeks. Safety assessments included serious adverse event reports, rates of discontinuation, spontaneously reported treatment‐emergent adverse events, changes in vital signs and laboratory values, and electrocardiograms. Results The rates of serious adverse events for duloxetine‐ and placebo‐treated patients were 0.3% and 0.6%, respectively (p = 0.282). Adverse events led to discontinuation in 9.7% of duloxetine‐treated patients, compared with 4.2% of patients receiving placebo (p < 0.001). Treatment‐emergent adverse events with an incidence for duloxetine ≥ 5.0% and significantly greater than placebo were nausea, dry mouth, constipation, insomnia, dizziness, fatigue, somnolence, increased sweating and decreased appetite. Mean changes in blood pressure and heart rate were small, and the incidence of increases above normal ranges was low. Duloxetine‐treated patients had a mean decrease in weight of 0.5 kg compared with an increase of 0.2 kg for patients receiving placebo (p < 0.001). No significant differences were found between duloxetine and placebo in the incidence of potentially clinically significant laboratory values at anytime while on treatment. Conclusion These results are consistent with those obtained previously from smaller pooled data sets, and suggest that duloxetine is safe and well tolerated in patients with MDD. Copyright © 2005 John Wiley & Sons, Ltd.
  • Publisher: Chichester, UK: John Wiley & Sons, Ltd
  • Language: English
  • Identifier: ISSN: 0885-6222
    EISSN: 1099-1077
    DOI: 10.1002/hup.696
    PMID: 15912562
  • Source: MEDLINE
    Alma/SFX Local Collection
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait